Dr. Trail is an internationally recognized expert in oncology drug research and development with over 35 years of experience including antibody-drug conjugates, bispecific T cell engagers, immunomodulatory antibodies, tumor-directed immune modulators and small molecule drugs. Her work has led to multiple IND filings and four approved oncology drugs. Dr. Trail has published extensively and is a co-inventor on multiple small molecule and biologic based patents. Dr. Trail has held senior leadership roles at Bristol-Myers Squibb, Bayer, Seattle Genetics, MedImmune, Regeneron and Molecular Partners.